We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,300 Open access books available
131,000 International authors and editors
160M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,300 Open access books available
131,000 International authors and editors
160M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter

Sarcoid Granulomas in Malignancy

Komal Arora, Neeraj Kaur and Jae Y. Ro

Abstract

Noncaseating epithelioid granulomas without accompanying systemic symptoms of sarcoidosis have been described in association with many primary tumors where they are designated as sarcoid-like (SL) reaction. Morphologically, this SL reaction is similar to granulomas found in systemic sarcoidosis comprising of focal accumulation of epithelioid cells and multinucleated giant cells. They can be seen either adjacent to the primary malignancy or in local draining lymph nodes. Additionally, sarcoid-like granulomas can affect other organs distant from the primary neoplasm, such as the spleen, bone marrow, and skin. This sarcoid-like reaction is thought to occur as an immunologic T-cell-mediated response to antigens expressed by the neoplastic cells or soluble tumor antigens. Whether the presence of this sarcoid-like reaction has any prognostic significance in the associated neoplasm is unclear.

Keywords: sarcoid-like granulomas, malignancy, prognosis

1. Introduction

Granulomatous inflammation is a type of chronic tissue reaction characterized histologically by accumulation of epithelioid cells and multinucleated giant cells. Sarcoidosis is a systemic granulomatous disorder of unknown etiology that affects various organs. Sarcoid-like (SL) granulomas/reactions can be seen in patients with malignant tumors without the history of systemic sarcoidosis. These reactions were first described by Wolbach in 1911 [1]. Subsequently, Herxheimer in 1917 reported sarcoideal granulomas in patients with carcinomas of breast, rectum, and cystic duct [2]. These granulomas can occur either within the primary tumor, adjacent to the primary malignancy, in local draining lymph nodes, or in organs distant from the primary malignancy such as the spleen, bone marrow, and skin. This SL reaction is thought to occur in response to antigens expressed by the neoplastic cell or soluble tumor antigens that trigger a T-cell-mediated local immune response. Other etiologies of granuloma formation in patients with malignancy are co-existing sarcoidosis, infectious etiology, and reaction to therapeutic drug or procedure. The SL granulomas have been reported to occur with an average frequency of 14% in Hodgkin lymphoma cases, 7% in non-Hodgkin lymphomas, 50% in seminomas, less than 1% in sarcomas, and 4% in various carcinomas [3, 4].
2. Histologic features

Morphologically, the granulomas of SL reaction are similar to those seen in sarcoidosis. The granulomas are comprised of central focus of epithelioid cells surrounded by a rim of lymphocytes. Both Langhans-type and foreign body-type giant cells containing asteroid body and Schaumann body inclusions have been reported [5, 6]. Usually, these granulomas are noncaseating with no central necrosis. In solid tumors such as renal cell carcinomas, the granulomas have been described in intratumoral and peritumoral location as well as in the nonneoplastic kidney and draining lymph nodes [7].

3. Pathophysiology

The granuloma formation in sarcoidosis is mediated by T-cells [8]. The granulomas in SL reactions are postulated to be a T-cell-mediated immunologic reaction to soluble tumor antigens shed by the tumor cells or released during tumor necrosis [3, 9]. In the study by Kurata et al., the authors found that the solitary granulomas in SL reactions first occur between lymph sinus and T-zone, the multiple granulomas mainly occur within T-zone, and the confluent types often occupy the whole lymph node except some residual lymphoid follicles [10]. Such a pattern suggested that the granulomas grow along the T-zone, where antigen presentation mainly occurs. Recently, some authors have also hypothesized that dendritic cells play an important role in the mechanism of T-cell activation that leads to formation of granulomas [10, 11].

SL reactions have also been reported after interferon therapy in patients with malignant melanoma and after interleukin-2 therapy for renal cell carcinoma [12, 13].

4. Prognostic significance

A dense lymphocytic infiltrate at the margins of some malignant tumors such as medullary carcinoma of the breast and colonic adenocarcinoma has been associated with an improved prognosis. This improved prognosis has been attributed to an immune-mediated cytotoxic T cell response to the tumor. Similarly, the SL reactions, which are thought to be an immune response to the tumor antigens, are expected to be associated with improved prognosis.

Currently, the prognostic significance of these SL granulomas is debatable. Some authors hypothesized that SL granulomatous reactions could play an important role in the host’s defense against metastatic spread [9, 14]. Several studies have shown that the presence of granulomas in Hodgkin’s disease correlated with improved survival in all stages of disease [15–17]. Similarly, SL reactions in gastric carcinoma have been reported to have a good prognosis [18]. Takeuchi et al. demonstrated that the incidence of SL reactions in the regional lymph nodes decreased as gastric cancer progressed [19]. In another study on seven cases of gastric cancer associated with SL reaction, none of the patients had any episodes of recurrence, suggesting a more favorable prognosis when compared with gastric cancer patients without a SL reaction [20].

SL reactions are relatively less common in solid tumors as compared to lymphomas. In a study by Lynch et al., the authors found that SL reaction was associated with improved prognosis in small cell carcinoma of the lung [21]. Recently, Steinfort et al. [22] studied eight patients with nonsmall cell carcinoma lung where sarcoideal granulomas were present in regional lymph nodes. The authors concluded that the
presence of sarcoidal reactions within regional lymph nodes of these patients predicted a lower rate of disease recurrence after definitive surgical resection. However, an earlier study by Kamiyoshihara et al. ruled out this hypothesis in lung cancer and found the SL reactions to be of no prognostic significance [23]. Similarly Tomimaru et al. studied 22 lung carcinoma patients with SL reaction in the regional lymph nodes and found no statistically significant difference in the overall survival [24]. Few cases of breast carcinoma and colorectal carcinoma associated with a stromal granulomatous SL reaction have been reported in the literature [25–30]. The authors were not able to make a definitive comment on the prognostic significance of these SL reactions in these published reports due to limited number of cases. Recently, we published the largest case series on SL reactions in renal cell carcinoma [7]. However, due to the limited follow-up and small number of cases, we could not conclude if these SL granulomas had any prognostic significance in renal cell carcinomas. We hypothesized that the high content of glycogen and lipid in tumor cells of clear cell and clear cell papillary renal cell carcinomas possibly triggered a granulomatous reaction, similar to that seen in seminomas.

In a recent case series published by Lashari et al., the authors reported the occurrence of granulomatous mediastinal lymphadenitis at a site remote from the location of primary gynecological malignancy without evidence of metastatic disease [31].

5. Sarcoidosis coexisting with malignancy

Sarcoidosis is associated with an increased risk for cancer development in various organs such as lung, liver, or stomach [32, 33]. Many hematologic malignancies and melanomas have also been associated with sarcoidosis. Coexistence of sarcoidosis and cancer has been associated with a diminished survival rate [34]. Sarcoidosis can present in patients before, during, or after diagnosis of malignancy [35, 36].

The association between systemic sarcoidosis and malignant lymphoma was first described by Brincker in 1986. The author used the term “Sarcoidosis-lymphoma syndrome” to describe this association [37]. It refers to development of lymphoma and other hematological malignancies after diagnosis of sarcoidosis as well as includes patients with lymphoma and hematological malignancies who subsequently develop sarcoidosis [35]. Differentiating between granulomas of systemic sarcoidosis and SL granulomas in patients with malignancy is difficult based on morphology alone. Diagnosis of systemic sarcoidosis is made in the presence of additional well-recognized clinical and radiological findings.

6. Diagnostic dilemmas

Radiologically, a SL reaction can mimic tumor recurrence/deposits in the draining lymph nodes. Hence, differentiating lymphadenopathy caused by a SL reaction and metastatic disease is very important clinically. Definitive diagnosis can be made only by histopathological examination of the lymph nodes.

Granulomas in the draining lymph nodes of malignancy can be both infectious as well as SL reaction. The center of these granulomas may sometimes have nests or isolated tumor cells. Hence, a close scrutiny of such granulomas should be performed to avoid missing metastatic disease. Immunostaining with cytokeratin may be required for recognizing these in difficult cases [38]. Knowledge of the usual tumor behavior along with correlating radiologic and histologic findings is important to avoid misdiagnosis.
Author details
Komal Arora¹, Neeraj Kaur² and Jae Y. Ro³*

1 University of Pittsburgh Medical Center Horizon Hospital, Farrell, PA, United States
2 University of Texas Health Science Center, San Antonio, TX, United States
3 Houston Methodist Hospital, United States

*Address all correspondence to: jaero@houstonmetodist.org
References


[17] Brincker H. Sarcoid reactions and sarcoidosis in Hodgkin's disease and


American Journal of Clinical Pathology. 1987;88:718-721


[34] Boffetta P, Rabkin CS, Gridley G. A cohort study of cancer among
Sarcoid Granulomas in Malignancy
DOI: http://dx.doi.org/10.5772/intechopen.92182


